SOPH Stock Overview
Operates as a cloud-native software technology company in the healthcare space. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
SOPHiA GENETICS SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.26 |
| 52 Week High | US$7.37 |
| 52 Week Low | US$2.70 |
| Beta | 0.99 |
| 1 Month Change | 2.84% |
| 3 Month Change | -14.88% |
| 1 Year Change | -28.38% |
| 3 Year Change | -76.12% |
| 5 Year Change | n/a |
| Change since IPO | -80.55% |
Recent News & Updates
Recent updates
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?
Oct 03
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Aug 09Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
Aug 08SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 09Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector
Feb 12Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge
Nov 09Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies
Sep 21SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M
Aug 09We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 18We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Nov 24Shareholder Returns
| SOPH | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -0.6% | -3.7% | -3.5% |
| 1Y | -28.4% | 0.7% | 22.1% |
Return vs Industry: SOPH underperformed the US Healthcare Services industry which returned 0.7% over the past year.
Return vs Market: SOPH underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| SOPH volatility | |
|---|---|
| SOPH Average Weekly Movement | 9.0% |
| Healthcare Services Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SOPH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SOPH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 430 | Jurgi Camblong | www.sophiagenetics.com |
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
SOPHiA GENETICS SA Fundamentals Summary
| SOPH fundamental statistics | |
|---|---|
| Market cap | US$205.96m |
| Earnings (TTM) | -US$71.40m |
| Revenue (TTM) | US$64.49m |
3.4x
P/S Ratio-3.0x
P/E RatioIs SOPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOPH income statement (TTM) | |
|---|---|
| Revenue | US$64.49m |
| Cost of Revenue | US$20.75m |
| Gross Profit | US$43.73m |
| Other Expenses | US$115.13m |
| Earnings | -US$71.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 67.82% |
| Net Profit Margin | -110.71% |
| Debt/Equity Ratio | 11.6% |
How did SOPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SOPHiA GENETICS SA is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Katie Tryhane | Credit Suisse |